Indian drugmaker Gujarat Themis Biosyn Ltd. has obtained private credit funding to back its purchase of Japanese peer MicroBiopharm Japan Co., highlighting the growing use of such debt for overseas expansion in Asia.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.